Statement of COVID-19 Variants For full details, please refer to the attached document below. --- Statement of COVID-19 Variants

Hefei, China – July 2025 — Anhui DEEPBLUE Medical Technology Co., Ltd. is pleased to announce that its Dengue NS1 & IgG/IgM Combo Test Kit (Colloidal Gold) has officially received the Medical Device Registration Certificate from the Medical Device Authority (MDA) of Malaysia, under the Medical Device Act 2012 (Act 737), Section 5(1). This certification confirms that the Dengue Combo Test Kit complies with Malaysian regulatory requirements and is officially approved for distribution and use in the Malaysian market. The test kit enables rapid and simultaneous detection of Dengue NS1 antigen and IgG/IgM antibodies, providing critical early diagnostic support for clinicians in managing dengue fever outbreaks. The recognition by Malaysia's regulatory authority highlights DEEPBLUE Medical’s commitment to high-quality diagnostics and international regulatory compliance, further expanding its presence in Southeast Asia. ------------------------------------------------------------------------ About Dengue Virus Dengue virus is a mosquito-borne virus primarily transmitted by Aedes aegypti mosquitoes. It belongs to the Flavivirus genus and has four distinct serotypes (DENV-1 to DENV-4). Dengue is commonly found in tropical and subtropical regions, with high prevalence in Southeast Asia, South Asia, Latin America, Africa, and parts of the Pacific Islands. Symptoms of Dengue typically appear 4–10 days after infection and may include: 1.High fever 2.Severe headache 3.Joint and muscle pain (often called "breakbone fever") 4.Skin rash 5.Nausea and vomiting 6.In severe cases, it can lead to Dengue Hemorrhagic Fever or Dengue Shock Syndrome, which can be life-threatening. Early detection and supportive care are key to effective management and prevention of complications.

From June 11 to 13, 2025, the global medical device industry turned its attention to the Miami Beach Convention Center in the United States, where the 2025 Florida International Medical Expo (FIME 2025) was held as scheduled. DEEPBLUE MEDICAL made a remarkable appearance at this prominent international event, showcasing its latest innovations and strong capabilities in the field of medical devices to a global audience. This marked DEEPBLUE MEDICAL’s second participation in FIME. As a leading Chinese enterprise specializing in the research, development, and manufacturing of medical devices, DEEPBLUE MEDICAL remains committed to delivering high-quality and high-performance rapid diagnostic test kits to customers worldwide. At this year’s exhibition, DEEPBLUE MEDICAL presented a carefully curated selection of its product lines, drawing significant attention from professional visitors across the industry:

On May 23, 2025, the 4-day International Medical Equipment Exhibition HOSPITALAR held in São Paulo, Brazil (hereinafter referred to as "HOSPITALAR") has successfully concluded. Jointly organized with the renowned German MEDICA exhibition and certified by the International Hospital Federation (IHF), HOSPITALAR has become the most authoritative medical device and supplies exhibition in Brazil and even the Latin American region since it was awarded the title of "Reliable Commercial Exhibition" by the U.S. Department of Commerce in 2000. As a national high-tech enterprise, Anhui DEEPBLUE Medical Technology Co., Ltd. (hereinafter referred to as "DEEPBLUE Medical") focuses on the R&D, production and sales of in vitro diagnostic reagents, medical devices and medical health products. This is the third time for DEEPBLUE Medical to appear at this exhibition, and the fruitful results of last year's participation have strengthened the company's determination to continue to deepen the Latin American market. At this exhibition, DEEPBLUE Medical stunningly launched a series of products with more than ten years of R&D accumulation, covering infectious disease detection, pet detection, drug detection, maternal and gynecological detection, female fertility detection and other series, which attracted many purchasers to stop by. To enhance the attractiveness of its products, DEEPBLUE Medical specially set up a product experience area at the booth, allowing customers to personally participate in disease detection experiences and intuitively feel the product advantages. Through this exhibition, DEEPBLUE Medical has not only further expanded its brand awareness in the Latin American region, but also established in-depth connections with many local and surrounding countries' trade professionals, laying a solid foundation for follow-up cooperation. In the future, DEEPBLUE Medical will continue to innovate and contribute more to the global medical and health cause through international exhibition platforms.

Hefei, China – March 2025 — Anhui Deepblue Medical Technology Co., Ltd. is pleased to announce that its SARS-CoV-2 & Influenza A/B Antigen Combo Self-Test Kit (Colloidal Gold) has officially received the EU Technical Documentation Assessment Certificate under REGULATION (EU) 2017/746 on In Vitro Diagnostic Devices (IVDR). The certification, issued by the EU Notified Body Sertio Oy, verifies that the product meets the stringent regulatory requirements outlined in Annex IX, Chapter II of the IVDR. This significant achievement affirms that Deepblue Medical’s self-testing solution has passed rigorous evaluations of safety, performance, and technical documentation. The three-in-one self-test kit is designed to detect SARS-CoV-2, Influenza A, and Influenza B antigens with high accuracy and speed. It empowers individuals to conduct reliable testing in non-clinical settings, facilitating early identification of respiratory infections and aiding in timely isolation and treatment decisions. This EU certification marks a major milestone for Deepblue Medical as the company continues to expand its presence in the European diagnostic market. It also underscores the company’s ongoing commitment to delivering high-quality, accessible, and regulatory-compliant diagnostic solutions globally. -------------------------------------- About Anhui Deepblue Medical Technology Co., Ltd. Anhui Deepblue Medical Technology Co., Ltd., headquartered in Hefei, China, is a leading manufacturer of rapid diagnostic tests. The company offers a wide range of solutions in women’s health, infectious disease detection, cardiovascular diagnostics, tumor markers, PCR testing, and drug screening. With global regulatory certifications and a strong focus on innovation, Deepblue Medical is dedicated to improving diagnostic efficiency and public health worldwide.

Anhui DEEPBLUE Medical Technology Co., Ltd. is a leading manufacturer of in vitro diagnostic reagents based in China, dedicated to advancing human health through innovative solutions. Our main product lines including Infectious Disease Test, Respiratory Disease Test, Tumor Marker Test, Drug of Abuse Test, Women Fertility Test, Renal Injury Test, Virus Sampling Tube (VTM) and other POCT tests. Through continuous innovation and optimization, we aim to deliver high-performance diagnostic solutions that meet diverse clinical needs and enhance overall healthcare standards. We firmly believe that scientific and technological advancements are essential for better serving human health and improving patient outcomes. We are proud to announce that Anhui Deep Blue Medical Technology Co., Ltd. has successfully obtained FDA 510(k) clearance for our home-use early pregnancy testing products. This milestone underscores our commitment to providing safe and effective diagnostic solutions for women's health. We appreciate the continued support of our partners and look forward to making a positive impact on women's health globally. For more information, please contact us at E.mail or phone.

On 28th November 2023, Anhui DEEPBLUE Medical Technology Co.,Ltd successfully passed the audit of MDSAP(Medical Device Single Audit Program) quality management system, and was awarded the certificate of MDSAP quality management system authentication (Certificate No.: No.QS6 003706 0004 (Certificate No. QS6 003706 0004 Rev.00). This quality management system certification brings DEEPBLUE more convenient access to the global market, which is conducive to improving product quality, safety, competitiveness and international market recognition, which will have a positive impact on DEEPBLUE's future development of the international market.

Hefei, China – March 2025 — Anhui DEEPBLUE Medical Technology Co., Ltd. is proud to announce that our innovative SARS-CoV-2 & Influenza A+B & RSV & ADV Antigen Combo Test Kit (Colloidal Gold) has officially obtained the European Union In Vitro Diagnostic Regulation (IVDR) certificates, including both the Self-Testing Certificate and the Quality Management System (QMS) Certificate. The certifications were issued by the notified body Sertio Oy, confirming compliance with REGULATION (EU) 2017/746. These certificates demonstrate that DEEPBLUE Medical's 5 in 1 antigen combo test kit meets the stringent requirements of Annex IX for Technical Documentation Assessment and Quality Management Systems under IVDR. This 5 in 1 combo test kit is designed to simultaneously detect SARS-CoV-2, Influenza A, Influenza B, Respiratory Syncytial Virus (RSV), and Adenovirus (ADV) antigens, offering rapid and reliable results to support early diagnosis and timely medical intervention. The successful acquisition of these EU certifications not only affirms DEEPBLUE Medical’s commitment to product quality, safety, and compliance but also enhances the accessibility of our diagnostic solutions across European markets. With a robust quality system and cutting-edge diagnostic technologies, DEEPBLUE Medical continues to uphold the highest international standards, providing trusted rapid testing solutions for global healthcare needs.   For more information, please visit our website or contact us directly.

To Whom It May Concern, We are excited to announce that Anhui DEEPBLUE Medical Technology Co. will be exhibiting at the upcomingAfrica Health 2024, taking place from October 22-24,2024 at Cape Town International Convention Centre, South Africa. We would like to extend a warm invitation for you to visit our booth H1.C29. At Anhui DEEPBLUE Medical Technology Co., we specialize in the production of in vitro diagnostic reagents, offering a wide range of products including women’s health test, infectious disease diagnostics test, drug screening, and PCR. Our commitment to quality and innovation in medical technology aims to enhance healthcare outcomes globally. We believe that this expo presents a great opportunity for us to connect, share insights, and explore potential collaborations. Our team will be on hand to discuss our latest developments and how our products can meet your needs. Please let us know if you can make it. We look forward to the opportunity to meet you in person and discuss how we can work together to advance healthcare solutions. Warm regards, Anhui DEEPBLUE Medical Technology Co., Ltd.

To Whom It May Concern, We are pleased to invite you to visit Anhui DEEPBLUE Medical Technology Co., Ltd. at the upcoming China International Medical Equipment Fair (CMEF), taking place from October 12 to 14, 2024. This prestigious event will be held at the Shenzhen Word Bxhibition & Convention Center. At CMEF, we will showcase our latest innovations and technologies in the medical field, aimed at improving healthcare solutions. Our team will be available to discuss how our products can meet your needs and enhance patient care. We would be honored to have you visit our booth [13B16] to explore potential collaborations and to learn more about our offerings. Your presence would greatly enrich the experience and foster meaningful connections. Thank you for considering our invitation. We look forward to welcoming you to our booth at CMEF. Best regards, Anhui DEEPBLUE Medical Technology Co., Ltd.

Dear Valued Partners and Healthcare Professionals, We are thrilled to invite you to visit Anhui DEEPBLUE Medical Technology Co., Ltd. at MEDICA 2024, the world's leading medical trade fair, taking place from November 11 to 14, 2024, in Düsseldorf, Germany. This global event gathers professionals and innovators in healthcare to showcase the latest advancements in medical technology. At this year’s MEDICA, we will present our cutting-edge rapid diagnostic solutions, including our latest developments in women’s health, infectious disease testing, cardiovascular markers, tumor markers, PCR testing, and drug detection. Our team of experts will be on hand to discuss how our products and technology can support your diagnostic needs and improve patient care. We warmly welcome you to visit our booth 3J34, where we will be delighted to explore potential partnerships and exchange insights to foster better healthcare solutions worldwide. Thank you for considering our invitation. We look forward to meeting you at MEDICA 2024 and sharing our latest innovations with you. Sincerely, Anhui DEEPBLUE Medical Technology Co., Ltd.

Recently, Anhui Deepblue Medical Technology Co., Ltd. (hereinafter referred to as DEEPBLUE) approved the approval of the China Council for the Promotion of International Trade CCPIT (hereinafter referred to as: CCPIT) evaluation, obtained the "Certificate of Export Commodity Brand", which is the national authority of DEEPBLUE export ability highly affirmed, is the future of the work of DEEPBLUE to further expand the overseas market, improve the international brand awareness and competitiveness of the international market. With the progress of social economy, brand building is particularly important in the process of enterprise development. Brand is an intangible asset of an enterprise, which reflects the economic strength, development level and overall image of an enterprise to a certain extent, and is an advantageous weapon for an enterprise in the fierce market competition. Vigorously implementing the brand strategy can not only help enterprises to establish a good corporate image and reputation, improve the trust of customers, but also help enterprises continue to expand the market, in the competition to occupy the advantage. In recent years, DEEPBLUE has accelerated the pace of participating in global competition and created a series of brands with good reputation, which is not only related to the development of enterprises, but also a strong embodiment of enhancing the comprehensive competitiveness of DEEPBLUE. In 2017, the establishment of the International Department of DEEPBLUE marked the formal entry of DEEPBLUE into the international market. In the process of hard struggle from weak to strong, from point to surface, DEEPBLUE relies on innovative technical strength, timely delivery ability, continuous improvement of after-sales service network and continuous optimization and adjustment of brand layout, adding bricks and tiles to "Deepblue Manufacturing" bit by bit, demonstrating the brand strength of DEEPBLUE. The certificate of export commodity brand is also a "cognitive method" for DEEPBLUE, which enables DEEPBLUE to have an in-depth understanding of the current situation and shortcomings of its own development, point out the direction for further improvement and development of the enterprise, and boost the implementation of the "going out" strategy. In the future, DEEPBLUE will be combined with the Suggestions for improvement of CCPIT, further implement the strategy of brand, comprehensive brand building layout, at the same time uphold the beginner's mind, give full play to accumulate and enterprise innovation advantage, strengthen intellectual property rights achievements transformation and product iteration, perfect the system of the intellectual property rights (ipr) protection, increasing foreign propaganda and comprehensive maintenance brand awareness and reputation, DEEPBLUE will further expand the international market of products and make greater contribution to building a carrier for the health industry.